L’Oréal Canada’s Nadia Petrolito recognized as one of WXN’s Canada’s Most Powerful Women

L’Oréal Canada’s Nadia Petrolito recognized as one of WXN’s Canada’s Most Powerful Women

Canada NewsWire

MONTRÉAL, Nov. 24, 2017 /CNW Telbec/ - L’Oréal Canada is pleased to announce that Nadia Petrolito, VP General Counsel/Chief Communications Officer is amongst Canada’s 2017 Most Powerful Women: Top 100 Award Winners. The announcement, made yesterday, paid tribute to the outstanding women across Canada who have advocated for diversity in the workforce, and who serve as an inspiration for the next generation of leaders. This year’s winners were recognized at a gala event in Toronto last night.

Nadia Petrolito, VP General Counsel/Chief Communications Officer, L'Oréal Canada. (CNW Group/L'Oréal Canada Inc.)

Co-presented by KPMG, the Top 100 Awards span the private, public and not-for-profit sectors, with recipients selected by an independent advisory board. The awards were given to remarkable women in 10 different categories and Ms. Petrolito won in the HSBC Corporate Executives category. Past Award Winners include some of Canada’s most iconic women trailblazers: Margaret Atwood, Best-Selling Author; Dr. Roberta Bondar, astronaut; Christine Magee, President, Sleep Country Canada; Michaëlle Jean, former Governor General of Canada; and Heather Reisman, Founder and CEO, Indigo Books & Music.

When asked how being described as “powerful” made her feel, Ms. Petrolito answered “For me, it is more about the power to influence, to change things and challenge the status quo. I am humbled to join WXN’s network of powerful women and I admire their mission dedicated to the advancement and recognition of women leaders and the promotion of diversity.

Nadia Petrolito joined L’Oréal Canada in July 2006 as a legal counsel and within a year she was leading the department. In her current role, she is in charge of the legal affairs and corporate communications departments and helps coordinates the corporate social responsibility program, Sharing Beauty With All. She is part of the group’s worldwide network of ethics correspondents and is a member of L’Oréal Canada’s executive committee.

For a full list of winners, please visit www.wxnetwork.com/top-100/top-100-winners.

About L’Oréal Canada

L’Oréal Canada is a wholly-owned subsidiary of L’Oréal Group, the largest cosmetics company in the world. Headquartered in Montreal, L’Oréal Canada had sales of $1.133 billion in 2016 and employs more than 1,300 people. The company holds a portfolio of 39 brands, encompassing all aspects of beauty, and is present across all distribution networks: mass market, department stores, salons, pharmacies, drugstores, and branded retail.


SOURCE L’Oréal Canada Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/November2017/24/c5607.html

More and Better Communication is Fundamental to Karen Adams Being Named One of Canada’s Most Powerful Women

More and Better Communication is Fundamental to Karen Adams Being Named One of Canada’s Most Powerful Women

Canada NewsWire

TORONTO, Nov. 24, 2017 /CNW/ – Karen Adams, President and CEO of Fundserv Inc., joins a prestigious list of iconic female leaders and visionaries after being named one of Canada’s Top 100 Most Powerful Women by the Women’s Executive Network. Adams was honoured at a gala celebration on November 23, 2017.

Karen Adams, President and CEO of Fundserv Inc. (CNW Group/Fundserv Inc.)

Adams brings an international, multi-industry perspective to Fundserv. Her career has spanned several continents, with senior positions in Mumbai, Shanghai, Hong Kong, Beijing, Seoul, Dubai, London, and Amman. This includes leading HSBC’s business in Jordan and Palestine.

“We are thrilled to celebrate this honour for our new CEO and to support the promotion of women leaders,” said Katherine MacMillan, Chair, Fundserv Board of Directors. “Fundserv is in very capable hands and is ready to embrace a bright future.”

After joining Fundserv just five months ago, Adams has quickly become an integral member of Fundserv’s executive team. Her ability to develop high-powered teams through employee engagement and communication has been critical as Fundserv seeks to further align its strategic direction with the needs of its members and the industry. 

“Karen is an extremely accomplished communicator and we are thrilled to have her leading Fundserv,” said Brad Badeau, Founding Chairman, Fundserv. “Congratulations Karen!”

“Karen is all about opening the doors and windows when it comes to communications – that’s the secret to her success as a leader,” said Don MacPherson, Partner, Deloitte Canada.

Before joining Fundserv, Adams served as President and CEO of Alberta Pension Services (APS), where she led the organization through a multi-year, $60 million, major technology and business improvement project.  

Founded in 2003, the Top 100 Awards honour the vision, drive, and success of Canada’s leading female executives, as well as their organizations and networks. They celebrate the incredible women who are the vanguards for change; overcoming obstacles, encouraging diversity, and challenging the next generation to continue the conversation.

Previous recipients of this honour include best-selling author, Margaret Atwood; CEO Arlene Dickinson; and former Governor General of Canada, Michaëlle Jean. The full list of WXN’s 2017 Canada’s Most Powerful Women: Top 100 Award Winners can be found at https://www.wxnetwork.com/top-100/top-100-winners/.

About Fundserv
Since 1993, Fundserv has connected the investment funds industry, delivering solutions that reduce time, cost, and risk, as well as fostering discussions that shape the way the industry operates. Fundserv’s goal is to provide reliability, innovation, and thought leadership, improving the ease of doing business by ensuring every trade is processed timely, accurately, and securely, so that its clients can focus on what matters most to their business.

Fundserv Inc. (CNW Group/Fundserv Inc.)

SOURCE Fundserv Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/November2017/24/c4639.html

Information Update – Health Canada safety review finds low incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) reported in Canada

Information Update – Health Canada safety review finds low incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) reported in Canada

Canada NewsWire

OTTAWA, Nov. 24, 2017 /CNW/ - Health Canada’s recent safety review of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) found that the rate of cases reported to the Department is low.

BIA-ALCL is a rare type of non-Hodgkin lymphoma (a cancer that affects the immune system) that may develop many months or years following a breast implant procedure. It is not a cancer of the breast tissue. BIA-ALCL usually presents as an accumulation of fluid (known as seroma fluid) between the implant and the surrounding tissue. The cause of BIA-ALCL is unknown. BIA-ALCL occurs with both saline-filled and silicone gel-filled breast implants.

Health Canada undertook the safety review because of an increase in reporting of BIA-ALCL internationally.

Five confirmed Canadian cases of BIA-ALCL have been reported by Canadian manufacturers in the last 10 years. This is equal to 1 case of BIA-ALCL per 77,190 implants sold, or 0.0013%. However, Health Canada acknowledges that some cases may not have been reported to the manufacturers or Health Canada during this time period.

Available data suggest that BIA-ALCL is more frequently reported with textured surface implants than smooth surface implants. Textured surface implants account for a quarter of all breast implants sold in Canada. Four of the five reported Canadian cases of BIA-ALCL involved textured surface implants. The surface type was not reported in the remaining case. The rate of occurrence of BIA‑ALCL per textured implant sold in Canada is 1 case per 24,177 or 0.0041%.

As a result of its safety review, Health Canada is working with manufacturers to update the safety information on the product labelling for all breast implants. Health Canada is also communicating this important safety information to Canadians through the Recalls and Safety Alerts database on the Healthy Canadians website.

Health Canada continues to monitor the safety profile of breast implants through its post-market surveillance program, to help ensure that the benefits of these products continue to outweigh the risks. Health Canada will also monitor cases of BIA-ALCL through an annual follow-up with manufacturers of breast implants. If new safety information is identified, Health Canada will take action as required.

What consumers should do

If you have breast implants

  • Conduct regular breast self-exams and see your surgeon for periodic follow-up.
  • If you experience unusual changes to your breasts, including breast pain, sudden swelling, or a lump, consult a healthcare professional who can send you for subsequent testing if necessary.
  • Removal of breast implants is not recommended if you do not have any signs or symptoms suggestive of BIA-ALCL.

If you are considering a breast implant

  • If you are considering a breast implant, you are encouraged to get more information and to consult with a healthcare professional about the risks and benefits associated with breast implants.
  • You can also find such information by visiting the breast implant section of the Health Canada website and consulting with your healthcare professional for more information. 

Information for healthcare professionals

  • Learn more about the signs, symptoms and testing steps to recognize and diagnose BIA‑ALCL.
  • Report incidents of BIA-ALCL to Health Canada. Include specific details, such as symptoms, how BIA-ALCL was discovered, age of patient at implantation, prior implant history, age of patient at discovery, tests conducted to diagnose, staging information, course of therapy and clinical outcomes.

Report health or safety concerns

To report a side effect to a health product to Health Canada:

  • Call toll-free at 1-866-234-2345.
  • Visit Health Canada’s webpage on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

Related links

Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

Également disponible en français


SOURCE Health Canada

View original content: http://www.newswire.ca/en/releases/archive/November2017/24/c8470.html